Impressum Bookmark Kontakt Sitemap

Hämoblastosen - Multiples Myelom (MM, Plasmozytom) - Weiterführende Informationen

Multiples Myelom (MM, Plasmozytom)

Leitlinien

 

www.dgho.de → onkopedia (Kortüm M et al. erstellt 07/10)

 

Studien

 

www.studien.de; www.myelom.net; www.lymphome.de; www.klinikum.uni-heidelberg.de/Klinische-Studien.118498.0.html

 

Literatur

 

  1. Attal M et al: Lenalidomid maintenance after transplantation for myeloma. J Clin Oncol 2010; 28 (suppl ASCO An-nual Meeting): abstr 8018
  2. Bladé J et al: Smoldering (asymptomatic) multiple myeloma: Current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 2010; 28: 690–7
  3. Dimopoulos et al: Lenalodomide plus Dexamathasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–32
  4. Greipp PR et al: International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–20
  5. Hillengass J et al: Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010; 28: 1606–10
  6. Kumar S: Treatment of newly diagnosed multiple myeloma in transplant-eligible patients. Curr Hematol Malig Rep 2011; 6: 104–12
  7. Kumar S et al: Trends in allogeneic stem cell transplantation for multiple myeloma: a center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Blood 2011; 118: 1979–88
  8. Ludwig H et al: Multiple myeloma treatment strategies with novel agents in 2011: A european perspective. On-cologist 2011; 16: 388–403
  9. McCarthy PL et al: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following sin-gle autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. J Clin Oncol 2010; 28 (suppl ASCO Annual Meeting): abstr 8017
  10. Morgan GJ et al: First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376: 1989–99
  11. Morgan GJ et al: Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX); secondary outcomes from a randomised controlled trial. Lancet Oncol 2011; 12: 743–52
  12. Palumbo A et Anderson K: Multiple Myeloma. N Engl J Med 2011; 364: 1046–60
  13. Ponisch W et al: Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone – a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132: 205–12
  14. Sonneveld P et al: First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing Bortezomib, Adriamycine, Dexamethasone (PAD) vs VAD as induction treatment prior to high dose Melphalan (HDM) in patients with newly diagnosed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2008; 112: abstr 653
  15. Van de Donk WCJ et al: Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2011; 37: 266–283